-
Product Insights
MRP Dev/ Union Invt RE – MIX Amsterdam Residential Complex – North Holland
The MRP Dev/ Union Invt RE – MIX Amsterdam Residential Complex – North Holland project involves the construction of six residential towers in Osdorpplein 1000, Amsterdam, the Netherlands. Equip yourself with the essential tools needed to make informed and profitable decisions with our MRP Dev/ Union Invt RE – MIX Amsterdam Residential Complex – North Holland report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days...
-
Company Insights
NewAir France – Digital Transformation Strategies
Air France-KLM Digital Transformation Strategies Overview Air France has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of Air France was estimated at $911.8 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Air France-KLM is an international airline group specializing in air passenger transport, cargo transport, and aircraft maintenance....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Non-Small Cell Lung Cancer Drug Details: ORM-5029 is...
-
Product Insights
Pulmonary Radiation Toxicity – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Radiation Toxicity - Drugs In Development, 2023’, provides an overview of the Pulmonary Radiation Toxicity pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Radiation Toxicity , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...
-
Product Insights
Familial Adenomatous Polyposis – Drugs In Development, 2023
Global Markets Direct’s, ‘Familial Adenomatous Polyposis - Drugs In Development, 2023’, provides an overview of the Familial Adenomatous Polyposis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Gastrointestinal Radiation Toxicity – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Radiation Toxicity - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Radiation Toxicity pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Radiation Toxicity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Leukodystrophies – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukodystrophies - Drugs In Development, 2023’, provides an overview of the Leukodystrophies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukodystrophies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenza A Virus, H7N9 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H7N9 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...